Market closedNon-fractional
TScan Therapeutics/TCRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About TScan Therapeutics
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Ticker
TCRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
164
Website
www.tscan.com
TCRX Metrics
BasicAdvanced
$380M
Market cap
-
P/E ratio
-$2.02
EPS
0.82
Beta
-
Dividend rate
Price and volume
Market cap
$380M
Beta
0.82
Financial strength
Current ratio
5.233
Quick ratio
5.171
Long term debt to equity
66.382
Total debt to equity
74.624
Interest coverage (TTM)
-27.14%
Management effectiveness
Return on assets (TTM)
-30.79%
Return on equity (TTM)
-96.32%
Valuation
Price to revenue (TTM)
23.222
Price to book
2.79
Price to tangible book (TTM)
2.79
Price to free cash flow (TTM)
-4.91
Growth
Revenue change (TTM)
-14.47%
Earnings per share change (TTM)
-32.92%
3-year revenue growth (CAGR)
68.21%
3-year earnings per share growth (CAGR)
-58.25%
What the Analysts think about TCRX
Analyst Ratings
Majority rating from 8 analysts.
TCRX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
-93.06%
Net income
-$30M
53.57%
Profit margin
-6,020.00%
2,111.45%
TCRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.51
-$0.24
-$0.21
-$0.32
-
Expected
-$0.78
-$0.45
-$0.29
-$0.26
-$0.28
Surprise
-34.36%
-46.90%
-27.59%
24.76%
-
TCRX News
AllArticlesVideos
TScan Therapeutics Announces Updates to its Board of Directors
GlobeNewsWire·1 month ago
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TScan Therapeutics stock?
TScan Therapeutics (TCRX) has a market cap of $380M as of July 27, 2024.
What is the P/E ratio for TScan Therapeutics stock?
The price to earnings (P/E) ratio for TScan Therapeutics (TCRX) stock is 0 as of July 27, 2024.
Does TScan Therapeutics stock pay dividends?
No, TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next TScan Therapeutics dividend payment date?
TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders.
What is the beta indicator for TScan Therapeutics?
TScan Therapeutics (TCRX) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell TScan Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.